1. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000; 342:605–612.
Article
2. Hariharan S. Long-term kidney transplant survival. Am J Kidney Dis. 2001; 38:6 Suppl 6. S44–S50.
Article
3. Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation. 1995; 59:1194–1200.
Article
4. Zand MS, Vo T, Huggins J, Felgar R, Liesveld J, Pellegrin T, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation. 2005; 79:1507–1515.
Article
5. Amlot PL, Rawlings E, Fernando ON, Griffin PJ, Heinrich G, Schreier MH, et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation. 1995; 60:748–756.
Article
6. Gralla J, Wiseman AC. The impact of IL2ra induction therapy in kidney transplantation using tacrolimus- and mycophenolate-based immunosuppression. Transplantation. 2010; 90:639–644.
Article
7. Castro MC, Araujo LM, Nahas WC, Arap S, David-Neto E, Ianhez LE. Induction versus noninduction therapy in kidney transplantation: considering different PRA levels and different induction therapies. Transplant Proc. 2004; 36:874–876.
Article
8. Ferrer F, Machado S, Alves R, Macário F, Bastos C, Roseiro A, et al. Induction with basiliximab in renal transplantation. Transplant Proc. 2010; 42:467–470.
Article
9. de Fijter JW. Rejection and function and chronic allograft dysfunction. Kidney Int Suppl. 2010; (119):S38–S41.
Article
10. Yarlagadda SG, Coca SG, Formica RN Jr, Poggio ED, Parikh CR. Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. Nephrol Dial Transplant. 2009; 24:1039–1047.
Article
11. Narayanan R, Cardella CJ, Cattran DC, Cole EH, Tinckam KJ, Schiff J, et al. Delayed graft function and the risk of death with graft function in living donor kidney transplant recipients. Am J Kidney Dis. 2010; 56:961–970.
Article
12. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006; 355:1967–1977.
Article
13. Lee KW, Park JB, Cho CW, Lee N, Yoo H, Kim K, et al. The impact of donor-specific anti-Human Leukocyte Antigen (HLA) antibody rebound on the risk of antibody mediated rejection in sensitized kidney transplant recipients. Ann Transplant. 2017; 22:166–176.
Article
14. Chen G, Gu J, Qiu J, Wang C, Fei J, Deng S, et al. Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function. Exp Clin Transplant. 2013; 11:310–314.
Article
15. Wang K, Xu X, Fan M. Induction therapy of basiliximab versus antithymocyte globulin in renal allograft: a systematic review and meta-analysis. Clin Exp Nephrol. 2018; 22:684–693.
Article
16. Moreira P, Sá H, Figueiredo A, Mota A. Delayed renal graft function: risk factors and impact on the outcome of transplantation. Transplant Proc. 2011; 43:100–105.
Article
17. Doshi MD, Garg N, Reese PP, Parikh CR. Recipient risk factors associated with delayed graft function: a paired kidney analysis. Transplantation. 2011; 91:666–671.
Article
18. Thiyagarajan UM, Ponnuswamy A, Bagul A. Thymoglobulin and its use in renal transplantation: a review. Am J Nephrol. 2013; 37:586–601.
Article
19. Gavela Martínez E, Sancho Calabuig A, Escudero Quesada V, Avila Bernabeu AI, Beltrán Catalán S, Morales García AI, et al. Induction treatment with low-dose thymoglobulin or basiliximab in renal transplants from older donors. Transplant Proc. 2008; 40:2900–2902.
Article
20. Gallinat A, Leerhoff S, Paul A, Molmenti EP, Schulze M, Witzke O, et al. Kidney transplantation from deceased donors with elevated serum creatinine. Langenbecks Arch Surg. 2016; 401:1211–1217.
Article
21. Williams RC, Opelz G, McGarvey CJ, Weil EJ, Chakkera HA. The risk of transplant failure with HLA mismatch in first adult kidney allografts from deceased donors. Transplantation. 2016; 100:1094–1102.
Article
22. Gill JS, Landsberg D, Johnston O, Shapiro RJ, Magil AB, Wu V, et al. Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection. Transplantation. 2010; 89:178–184.
Article
23. Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van, Mooney N, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013; 369:1215–1226.
Article
24. Brokhof MM, Sollinger HW, Hager DR, Muth BL, Pirsch JD, Fernandez LA, et al. Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients. Transplantation. 2014; 97:612–617.
Article
25. Pascual J, Zuckermann A, Djamali A, Hertig A, Naesens M. Rabbit antithymocyte globulin and donor-specific antibodies in kidney transplantation: a review. Transplant Rev (Orlando). 2016; 30:85–91.
Article
26. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007; 357:2601–2614.
Article
27. Sagedal S, Nordal KP, Hartmann A, Sund S, Scott H, Degré M, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant. 2002; 2:850–856.
Article
28. Erdbrügger U, Scheffner I, Mengel M, Schwarz A, Haller H, Gwinner W. Long-term impact of CMV infection on allografts and on patient survival in renal transplant patients with protocol biopsies. Am J Physiol Renal Physiol. 2015; 309:F925–F932.
Article